Ethical considerations in rapid and novel treatments in psychiatry
Tobias Haeusermann, Winston Chiong
Neuropsychopharmacology January 1, 2024 DOI: 10.1038/s41386-023-01635-y via Springer Nature
Summary
AI-generated from the abstractNew treatments for mental illness, including psychedelics, ketamine, and neuromodulatory technologies, raise novel ethical questions alongside familiar ones in clinical care and research. This overview examines three key domains of ethical concern: informed consent, the role of expectancy in clinical response, and distributive justice. The authors introduce these issues without presenting empirical findings.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Key finding | Novel treatments for mental illness raise ethical questions in the domains of informed consent, expectancy, and distributive justice. |
Abstract
New treatment modalities for mental illness are deeply needed, and emerging therapeutic agents such as psychedelics, ketamine, and neuromodulatory technologies have been welcomed by many researchers and patients. These treatment approaches have also been observed to raise novel ethical questions, and to pose new and different versions of familiar ethical questions in clinical treatment and research. We present an overview and introduction to these issues organized around three specific domains of ethical concern: informed consent, the role of expectancy in clinical response, and distributive justice.